Balyasny Asset Management LLC Intercept Pharmaceuticals, Inc. Transaction History

Balyasny Asset Management LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$11.61 - $16.11 $3.9 Million - $5.42 Million	336,332 Added 1212.62%	364,068 $4.5 Million
Q3 2022 Nov 14, 2022	BUY	$12.21 - $19.7 $211,916 - $341,913	17,356 Added 167.21%	27,736 $387,000
Q2 2022 Aug 15, 2022	BUY	$11.23 - $19.59 $116,567 - $203,344	10,380 New	10,380 $143,000
Q1 2022 May 16, 2022	SELL	$13.37 - $17.79 $258,482 - $343,934	-19,333 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$14.28 - $19.53 $3.16 Million - $4.32 Million	-221,398 Reduced 91.97%	19,333 $315,000
Q3 2021 Nov 15, 2021	BUY	$12.99 - $20.47 $3.13 Million - $4.93 Million	240,731 New	240,731 $3.58 Million
Q2 2020 Aug 14, 2020	SELL	$46.7 - $92.04 $254,001 - $500,605	-5,439 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$48.35 - $118.68 $2.67 Million - $6.55 Million	-55,156 Reduced 91.02%	5,439 $342,000
Q4 2019 Feb 14, 2020	BUY	$57.36 - $124.1 $3.48 Million - $7.52 Million	60,595 New	60,595 $7.51 Million
Q4 2018 Feb 14, 2019	SELL	$85.79 - $126.46 $1.89 Million - $2.78 Million	-22,000 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$88.49 - $127.55 $2.08 Million - $3 Million	-23,534 Reduced 51.68%	22,000 $2.78 Million
Q2 2018 Aug 14, 2018	BUY	$60.0 - $85.67 $2.73 Million - $3.9 Million	45,534 New	45,534 $3.82 Million
Q1 2018 May 15, 2018	SELL	$52.72 - $67.25 $2.67 Million - $3.41 Million	-50,716 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$58.2 - $72.76 $5.28 Million - $6.6 Million	-90,684 Reduced 64.13%	50,716 $2.96 Million
Q3 2017 Nov 14, 2017	BUY	$57.01 - $118.75 $8.06 Million - $16.8 Million	141,400	141,400 $8.21 Million

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.